Skip to main
  1. Stocks
  2. Damora Therapeutics, Inc.
  3. Forecast
DMRA

DMRA Stock Forecast & Price Target

DMRA Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Damora Therapeutics is attractive fundamentally because DMR-001 has already entered the clinic, with FDA-cleared IND status and Phase 1 dose-escalation enrolling at multiple U.S. sites, while a Bayesian adaptive design and more than 50 selected global sites could speed dose-finding and expansion. Its preclinical profile is especially compelling: DMR-001 binds both Type 1 and Type 2 mutCALR, showed a mean 95-fold potency improvement across non-Type 1 variants, and offers monthly subcutaneous dosing that may be meaningfully more convenient than competing IV or biweekly approaches. Financially, the company’s $528.5M in cash, cash equivalents, and marketable securities is expected to fund operations into 2H 2029, covering proof-of-concept readouts starting in mid-2027 and planned Phase 3 timing in mid-2028 while DMR-002 and DMR-003 add additional pipeline value.

Bears say

Damora Therapeutics is viewed negatively because its lead program, DMR-001, faces substantial clinical execution risk, including IND submission delays, manufacturing challenges, slower-than-expected enrollment, and the possibility that the mid-2027 Ph 1 POC readout disappoints or fails to show meaningful improvement versus INCA033989. The commercial thesis is also weakened by INCA033989’s 2-3 year head start, which could let a rival capture much of the addressable mutCALR population before Damora can prove durable efficacy or SC Q4W tolerability. More broadly, the target market is difficult because existing MF therapies such as Jakafi and other JAK-based approaches are limited by toxicity, dose reductions, and incomplete effectiveness, making Damora highly dependent on flawless differentiation in a crowded and unforgiving clinical landscape.

DMRA has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Damora Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

DMRA Analyst Forecast & Price Prediction

Get the latest DMRA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DMRA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Damora Therapeutics, Inc. (DMRA) Forecast

Analysts have given DMRA a Buy based on their latest research and market trends.

According to 6 analysts, DMRA has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Damora Therapeutics, Inc. (DMRA)


DMRA Analyst Forecast & Price Prediction

Get the latest DMRA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DMRA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DMRA stock data and trends